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Abstract
Background: Recent findings support a connection between mitochondrial dysfunction and activation of inflammatory
pathways in articular cells. This study investigates in vivo in an acute model whether intra-articular administration of
oligomycin, an inhibitor of mitochondrial function, induces an oxidative and inflammatory response in rat knee joints.
Methods: Oligomycin was injected into the rat left knee joint on days 0, 2, and 5 before joint tissues were obtained on
day 6. The right knee joint served as control. Results were evaluated by macroscopy and histopathology and by
measuring cellular and mitochondrial reactive oxygen species (ROS), 4-hydroxy-2-nonenal (4-HNE, a marker of lipid
peroxidation), nuclear factor erythroid 2-related factor 2 (Nrf2), and CD68 (macrophages) and chemokine levels. The
marker of mitochondrial mass COX-IV was also evaluated.
Results: The macroscopic findings showed significantly greater swelling in oligomycin-injected knees than in control
knees. Likewise, the histological score of synovial damage was also increased significantly. Immunohistochemical studies
showed high expression of IL-8, coinciding with a marked infiltration of polymorphonuclears and CD68+ cells in the
synovium. Mitochondrial mass was increased in the synovium of oligomycin-injected joints, as well as cellular and
mitochondrial ROS production, and 4-HNE. Relatedly, expression of the oxidative stress-related transcription factor Nrf2
was also increased. As expected, no histological differences were observed in the cartilage; however, cytokine-induced
neutrophil chemoattractant-1 mRNA and protein expression were up-regulated in this tissue.
Conclusions: Mitochondrial failure in the joint is able to reproduce the oxidative and inflammatory status observed in
arthritic joints.
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Background
Multiple studies indicate that reactive oxygen species
(ROS) production is increased in rheumatic diseases
(e.g., rheumatoid arthritis (RA) or osteoarthritis (OA))
leading to oxidative stress which may contribute to ar-
ticular damage and hence to the chronicity of these
pathologies. In fact, a correlation between the disease ac-
tivity of arthritis and the presence of oxidative stress has
been described [1, 2]. ROS and oxidative damage includ-
ing lipid peroxidation, protein oxidation, or DNA lesions
actively participate in pathological processes in the
joint, among them, actively participate in pathological
processes in the joint, including activation of inflamma-
tory and destructive responses [1, 3]. Thus, the over-
activation of pro-inflammatory pathways in the joint
drives the pathogenesis of articular diseases [4–6]. Like-
wise, synovial inflammation is strongly correlated with
progression of inflammatory arthritis [7], and similarly,
plays an important role in the onset of articular dis-
eases not classically considered inflammatory such as
OA [4, 6]. Finally, drugs commonly used in treatment
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of chronic arthropathies exert their effect through
modulating oxidative processes [1, 8].
Mitochondria play a pivotal role in maintaining of
redox homeostasis since, they are both the major pro-
ducers and the major targets of ROS in the cell [9]. As a
consequence, oxidative damage to mitochondria may
lead to respiratory chain dysfunction, which results in
increased ROS levels, leading to a vicious cycle of oxida-
tive stress [10]. In fact, a decline in mitochondrial func-
tion has been linked to rheumatoid disorders [11–16].
Specifically, a deficiency in one subunit of the mitochon-
drial respiratory chain (MRC) complex IV is observed in
the synovium of RA and juvenile idiopathic arthritis
(JIA) [17, 18]. Moreover, OA chondrocytes show de-
creased activity of MRC complexes I, II, and III [13].
Additionally, a growing number of studies have demon-
strated the involvement of mitochondrial damage in dif-
ferent aspects of articular diseases, e.g., autoimmunity
[19], or the hypoxic state of synovial tissue in RA [17],
and several pathways associated with cartilage degrad-
ation in OA pathology [16, 20–25]. Pro-inflammatory
mediators, which are highly produced in these disorders,
may also alter mitochondrial function of human syno-
viocytes and chondrocytes [22, 26–28], reinforcing the
strong link between mitochondrial defects and oxidative
stress and inflammation [29].
Previously, it has been shown that oligomycin, an inhibi-
tor of mitochondrial complex V, induces an oxidative,
inflammatory, and destructive response in cultured hu-
man normal synoviocytes and chondrocytes [20, 23, 30].
However, despite the potential involvement of mitochon-
drial dysfunction in arthropathies, no studies in vivo have
evaluated the direct effect of mitochondrial damage by oli-
gomycin on the joint. Therefore, the aim of this study was
to analyze in vivo in an acute model whether mitochon-
drial defects can reproduce the oxidative and inflamma-
tory status observed in arthritic joints. Additionally, we
examined whether a differential response could take place
in articular tissues. Finally, we also evaluated the expres-
sion of the nuclear factor erythroid 2-related factor 2
(Nrf2), a redox-sensitive transcription factor responsible
for preserving the cellular defense against oxidative over-
load [31, 32].
Methods
In vivo model of joint damage induced by mitochondrial
dysfunction
Twenty-seven female Wistar rats (Harlan Interfauna
Ibérica, Barcelona, Spain) weighing between 180 and
220 g (4 months) were used. The animals were kept at
room temperature (20-24 °C) and commercial food and
water was available ad libitum. Rats were randomly
assigned into three groups: healthy group (in which rats
were not injected); oligomycin group (O4876, Sigma,
San Luis, MO, USA) employed as mitochondrial com-
plex V inhibitor [30, 33, 34] (in which the left knee joints
were injected intra-articularly with 20 μg oligomycin in
30 μl vehicle [oligomycin-injected joints], and the right
knee joints were injected with an equal volume of ve-
hicle [oligomycin-vehicle], containing the same amount
of DMSO); and the lipopolysaccharide (LPS) group
(Sigma), employed as positive control of inflammatory
signs [35, 36] (in which the left knee joints were injected
intra-articularly with 10 μg LPS in 30 μl vehicle [LPS-
injected joints], and the contralateral joints with its ve-
hicle [LPS-vehicle]). The dose of oligomycin was chosen
based on prior works with this mitochondrial inhibitor
in rats [34] and pilot experiments where we found that
the employed dose, 0.1 mg/kg, had an inflammatory
response and was neither signs of acute toxicity (con-
vulsion, hypoactivity, weakness and ataxia). The oligo-
mycin was dissolved in Dimethyl Sulfoxide (DMSO) at
50 mg/ml and stored at −20 °C. For injection, the stock
solution was mixed with 0.1% bovine serum albumin
(BSA) in Phosphate buffered saline (PBS). All animal
manipulations and intra-articular injections, which were
carried out by a 26G needle, were performed under
Sevorane™ (AbbVie, Madrid, Spain) anesthesia. The time
course of this acute articular model is based on previous
literature [35, 37]. Intra-articular injections were carried
out on days 0, 2, and 5, and rats were euthanized on day
6 being deeply anesthetized with Sevorane™ and after
performing the extraction of the blood, their deaths will
be induced by anesthetic overdose. Hind joints were dis-
sected and processed either as a whole, or joint tissues
were obtained separately. Five animals for each group
(healthy, oligomycin and LPS) were employed to make
the histological analysis and immunohistochemistry
studies; 7 other animals for oligomycin group were
employed to evaluate, in synovial membrane, the cyto-
solic and mitochondrial ROS, cytochrome c oxidase sub-
unit IV (COX-IV), and CINC-1 levels by ELISA in
cartilage; and 5 more animals for oligomycin group were
used to analyze the cartilage gene expression.
Human samples
Human synovial tissue was obtained at time of total joint
replacement surgery or above-the-knee amputations
from patients with no history of joint disease (mean ± SD
age 74 ± 8 years; n = 8), or with OA (mean ± SD age
70 ± 7 years; n = 8). All studies were performed strictly
in accordance with current local ethics regulations.
Joint swelling score
The severity of arthritis, indicated by joint swelling, was
quantified by measuring the knee joint diameter using a
digital caliper (S-CalWork, Sylvac, Malleray, Switzerland)
by two blinded observers on days 0, 2, 5, and 6. The
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results are expressed as the difference (delta, Δ) between
the joint size in mm at days 2, 5, or 6 and the joint size be-
fore the first intra-articular injection (day 0).
Histological analysis
Knee joints from rats injected intra-articularly with oli-
gomycin and its vehicle (n = 5) were dissected, fixed in
4% formaldehyde in PBS, decalcified with Shandon
TBD-1 (Thermo Fisher Scientific Inc., Waltham, MA,
USA), and embedded in paraffin (frontal section). Le-
sions in the synovial tissue and cartilage were evaluated
by semi-quantitative analysis by two blinded researchers
using an Olympus microscope (Olympus BX61, Olym-
pus Biosystems, Barcelona, Spain). Sections (4-μm thick)
of the joint were stained with hematoxylin and eosin or
Safranin O-fast green (Merck, Madrid, Spain) for this
purpose. Two samples per animal and five microscopic
fields each sample at 20X magnification were used to
evaluated damage score for synovial and cartilage tissue,
respectively. According to the semi-quantitative modi-
fied OARSI score, the grade of the synovial lesion was
scored from 0 to 4 (0 being not damaged and 4 most
damaged), and the evaluation parameters were: numbers
of lining cell layers, proliferation of the subintima tissue,
infiltration of inflammatory cells, and pannus formation
[38]. The grade of the cartilage lesion was scored from 0
to 13 (0 being not damaged and 13 most damaged) by
evaluating the structure, cellular abnormalities, and
matrix staining of the cartilage [39]. The percentage of
polymorphonuclear leukocytes (PMN) in the synovial in-
filtrate was identified by evaluating hematoxylin and
eosin-stained joint sections.
Immunohistochemistry and immunofluorescence
IL-8, CD-68, Nrf2, and 4-hidroxi-2-nonenal (4-HNE)
were evaluated on sections rats from paraffin-embedded
joint, while those for COX-IV were evaluated on frozen
sections. Additionally, Nrf2 immunohistochemistry ana-
lysis was also carried out on synovial tissue from healthy
and OA patients. Paraffin-embedded sections were first
deparaffinized with xylene and then rehydrated in
graded ethanol and water. For antigen unmasking, sec-
tions were placed in citrate buffer (pH 6.0; Dako,
Glostrup, Denmark) and heated in a pressure cooker.
Endogenous peroxidase activity was quenched using a
commercial reactive (Dako) for 10 min. After washing in
PBS, slides were incubated overnight at 4 °C with anti-
IL-8 (1:150, Abcam, Cambridge, UK) or anti-CD68
(1:100, Abcam) antibodies, or 1 h at room temperature
with anti-Nrf2 (1:300; Abcam) or anti-4-HNE (1:150,
Abcam) antibodies. Bound antibodies were detected with
a secondary antibody and diaminobenzidine using the
commercial EnVision™ Detection System (Dako). Finally,
sections were counterstained with Gill III hematoxylin
(Merck) and mounted with DePeX (Sigma). For COX-IV
analysis, frozen cryostat sections (6-μm thick) of synovial
membrane were fixed for 15 min in 4% formaldehyde in
PBS, and blocked with 10% horse serum for 1 h in PBS
with 0.3% Triton X-100. A rabbit anti-COX-IV (1:200;
Abcam) antibody was incubated in PBS with 0.1% Triton
X-100 overnight at 4 °C. After rinse, secondary antibody,
donkey anti-rabbit antibody alexa 488 (1:500; BD
Biosciences Pharmigen, San Diego, CA, USA; fluores-
cence signal green) was incubated during 1 h at room
temperature. Another washing process was then applied,
and finally the slides were counterstained with the nu-
clear marker 4′,6-diamidino-2-phenylindole (DAPI,
Sigma; fluorescence signal blue), and coverslipped using
fluorescent mounting medium (Dako). Multiple images
of each slide were captured with a computer-controlled
digital camera (Olympus BX61, Olympus). By using an
image processing software (Image J software, http://ima-
gej.nih.gov/), the area of the synovial tissue presenting a
positive signal of immunostaining was measured and
represented as the percentage of the positive area of syn-
ovial tissue in relation to total area of synovium.
In situ detection of cytosolic and mitochondrial ROS
ROS levels in the synovial tissue from knee joints
injected intra-articularly with oligomycin or its vehicle
were analyzed ex vivo by a modified method for meas-
urement of ROS generation using superoxide-sensitive
fluorophores [40]. The oxidative fluorescent indicator
dihydroethidium (DHE; Sigma; fluorescence signal red)
was used to evaluate the cytosolic production of ROS,
whereas the mitochondrial one was estimated using the
MitoSOX™ Red Mitochondrial Superoxide Indicator
(MitoSOX, Life Technologies, Carlsbad, CA, USA; fluor-
escence signal red). Frozen sections of synovial mem-
brane (6 μm) were incubated with DHE (2 μM) or
MitoSOX (1 μM) in a humidified chamber and protected
from light for 30 min at 37 °C. Then, sections were fixed
for 15 min in 4% paraformaldehyde in PBS, counter-
stained with the nuclear marker DAPI (fluorescence sig-
nal blue), and coverslipped using fluorescent mounting
medium. To detect red fluorescence, excitation was at
405 nm with the emission collected through a 605/15 fil-
ter. To validate the specificity of the fluorescence probes,
adjacent slides were preincubated with the superoxide
dismutase (SOD; 250 U/ml; Sigma) for 30 min at 37 °C
before coincubation with ROS detectors. Multiple im-
ages were captured with a computer-controlled digital
camera (Olympus BX61, Olympus) and the positive
DHE or MitoSOX fluorescence signal (red) of whole
synovial tissue was quantified by Image J software and
normalized with DAPI (blue).
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Analysis of gene expression
Cartilage slices were obtained from the rat knee joint,
and samples were frozen, and powdered. RNA from
tissue was extracted with the TRIzol Reagent method
(Invitrogen, Paisley, UK), and RNA (1 μg) was treated
with DNase (Invitrogen), and retro-transcribed with
Superscript® VILO™ (Invitrogen). Real-time polymerase
chain reaction analysis for gene expression of cytokine-
induced neutrophil chemoattractant-1 (CINC-1) and of
the housekeeping gene hypoxanthine phosphoribosyl-
transferase (HPRT) was performed using a LightCycler
480 SYBR Green I Master kit and the LightCycler 480
II PCR system (Roche Diagnostics, Abingdon, UK) by
delta delta CT analysis method. The gene-specific pri-
mer pairs used were as follows: CINC-1, forward 5′-
cacactccaacagagcacca-3′, reverse 5′-tgacagcgcagctcattg-
3′; and HPRT, forward 5′-gaccggttctgtcatgtcg-3′, re-
verse 5′-acctggttcatcatcactaatcac-3′.
CINC-1 analysis by ELISA
Cartilage slices from knee joints injected intra-articularly
with oligomycin or its vehicle were obtained upon sacrifice
and incubated 24 h at 37 °C in Dulbecco’s modified Eagle’s
medium (DMEM, Gibco Life Technologies, Paisley, UK).
Rat CINC-1 content in the supernatants was measured
with an ELISA (Quantikine® R&D System, Abingdon, UK)
according to the manufacturer’s recommendations. In
order to normalize the obtained concentrations, total DNA
from tissue was extracted by TRIzol Reagent method. Data
are expressed as pg protein released per μg of DNA.
Statistical analysis
Data are presented as the mean ± SEM or as representa-
tive results, as indicated. Tissues from different animals
were pooled when indicated. The GraphPad PRISM ver-
sion 5 statistical software package (La Jolla, CA, USA)
was used to compare experimental groups by Wilcoxon’s
paired comparison test. In addition, we employed the
Mann-Whitney U test to analyze the differences in Nrf-2
expression from synovial tissue of healthy vs. OA pa-
tients. P < 0.05 was considered statistically significant.
Results
Oligomycin induces joint swelling and inflammatory
changes in the synovial tissue
Animals injected with oligomycin developed significantly
more joint swelling than contralateral oligomycin-
vehicle knees (P ≤ 0.005) (Fig. 1a). Oligomycin clearly in-
creased articular swelling by day 2, and maintained
incremental increases in swelling over time, achieving
the highest changes on day 6 (oligomycin: 1.9 ± 0.2 mm,
oligomycin-vehicle: 1.0 ± 0.1 mm). As expected, LPS-
injected knees also significantly increased in joint thick-
ness (P ≤ 0.001).
Pathological alterations in synovial tissue were ana-
lyzed by conventional staining methods. Oligomycin-
injected joints showed evident synovitis, with a clear
increase in the number of lining cell layers, proliferation
of subintima tissue, and cell infiltration (Fig. 1b). In
agreement with the results of previous studies [35, 36],
LPS-injected joints exhibited significant synovial hyperpla-
sia, with a high number of inflammatory cells (Fig. 1b).
The semi-quantitative modified OARSI score confirmed
significantly more severe pathological changes observed in
the synovium of oligomycin-injected joints than of
vehicle-injected control knees (P ≤ 0.05) (Fig. 1c). In par-
ticular, morphological analysis showed that after oligomy-
cin injection, there was substantial infiltration of PMN
into the synovial membrane (Fig. 1d). See Additional file
1: Figure S1 for complete histology images. Moreover, we
also confirmed, by immunohistochemical analysis, a sig-
nificantly higher number of CD68+ cells in the synovial
infiltrate from LPS- and oligomycin-injected joints than
from vehicle-injected control joints (Fig. 2a and c)
(P ≤ 0.05).
IL-8 is a chemokine characterized by attracting neu-
trophils at the site of inflammation, which plays a pivotal
role in arthritis pathogenesis [5]. By immunohistochemi-
cal analysis, we evaluated the IL-8 protein expression in
the synovium. The results indicated significantly
(P ≤ 0.05) higher IL-8 protein expression in the synovial
tissue of LPS- and oligomycin-injected joints than of
vehicle-injected control knees (Fig. 2b and d).
Oligomycin triggers an oxidative response and a
mitochondrial alteration in the synovial tissue
We previously described that oligomycin induces an in-
crease in ROS production on cultured synoviocytes and
chondrocytes [30, 41]. Here, we evaluated cellular and
mitochondrial ROS ex vivo in synovial tissue using
superoxide-sensitive fluorophores. The results showed
that synovium from oligomycin-injected joints presented
a more significant increase in ROS production at both
cellular (Fig. 3a and c) and mitochondrial levels (Fig. 3b
and d) than from vehicle-injected control joints
(P ≤ 0.05). We also assessed COX-IV signal since this
protein is considered to be a marker of mitochondrial
mass [42]. Figure 4a and b, show an increase (P ≤ 0.05)
in COX-IV expression in the synovial tissue from the
oligomycin group, as compared with the control group.
Oligomycin exposure causes an increase in lipid
peroxidation and Nrf2 activation
One footprint of ROS is membrane lipid peroxidation.
For this reason, we determined the presence of oxidative
damage in synovial tissue by immunohistochemistry of
4-HNE, a maker of lipid oxidation. We observed a sig-
nificantly greater signal of 4-HNE staining of synovial
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tissue from oligomycin-injected joints (P ≤ 0.05) than
from synovial tissue from vehicle-injected control joints
(Fig. 5a and d).
4-HNE is able to enhance gene expression of antioxi-
dant and detoxifying enzymes through the redox-
sensitive transcription factor Nrf2 [43]. Besides, it has
been described that Nrf2 is activated in the synovial tis-
sue of patients with RA and of arthritic mice [31]. In our
model, immunohistochemical analysis of Nrf2 showed
that oligomycin injection into the knee significantly in-
creased the Nrf2 expression in the synovial tissue
(P ≤ 0.05) (Fig. 5b and e), compared with vehicle-
injected control tissue. Confirming our findings in mur-
ine joint, we observed that synovial lining from patients
with advanced OA (K/L grade 3-4) presents a
significantly higher Nrf2 levels compared with that from
healthy patients (P ≤ 0.05; n = 8) (Fig. 5c and f).
Oligomycin activates CINC-1 expression in the cartilage
As expected, because of the short time period of the
study, no significant histopathological alterations were
observed in the cartilage oligomycin-injected joints
(Fig. 6a). Nevertheless, we observed modulation at
molecular level in the cartilage of intra-articular
oligomycin-injected joints by analyzing the pro-
inflammatory chemokine CINC-1 (a murine homologue
of human IL-8, commonly up-regulated in articular
pathologies [5]. As shown in Fig. 6b, CINC-1 gene ex-
pression was significantly higher in cartilage from
oligomycin-injected rats than from vehicle-injected
Fig. 1 Oligomycin can induce joint swelling and inflammatory changes in the synovial tissue. a Knee joint swelling as an indicator of inflammation is
estimated from joint width (as described in Methods). Values are mean ± SEM (n = 5). *P ≤ 0.005 and **P ≤ 0.001 vs contralateral vehicle-injected
knees. b Representative images of synovial tissue stained with hematoxylin and eosin from each group of study. c Semi-quantitative score of
pathological alterations in synovial tissue as described in Methods. Data represent mean ± SEM (n = 5 independent samples for each condition). *P ≤ 0.05
vs contralateral vehicle-injected knees. d Percentage of PMN was analyzed as described in Methods. Values are mean ± SEM (n = 5 independent synovial
tissues for each condition). *P ≤ 0.05 vs contralateral vehicle-injected knees. LPS, lipopolysaccharide; OLI, oligomycin
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control joints (P ≤ 0.05). To confirm at the protein level
the increase in CINC-1 mRNA expression induced by
oligomycin, ex vivo experiments were carried out in
cartilage slices from the oligomycin group. A greater
release of CINC-1 protein was observed in oligomycin-
injected cartilage than in vehicle-injected control cartilage
(Fig. 6c), supporting observations at the mRNA level.
Discussion
Previous studies by other groups [11, 12, 16, 20, 22] and
by us [13, 23, 25, 30, 44, 45] revealed that a decline in
mitochondrial function could be implicated in arthritis
pathogenesis. Most of these studies were performed
under in vitro or ex vivo conditions and, strikingly, few
studies have evaluated the effect of mitochondrial dys-
function on an in vivo model [17, 19, 21]. Collins et al.
have shown clearly that mitochondrial DNA (mtDNA) is
immunostimulatory in the mouse knee joint [19]. It has
also been suggested that a decline of mitochondrial bio-
energetic reserve, resulting from mitochondrial dysfunc-
tion, may contribute to a negative balance of matrix
synthesis and degradation of cartilage in a spontaneous
model of OA [21]. In this study, we report, for the first
time, the acute effect in vivo of the intra-articular injec-
tion in the rat knee of a mitochondrial inhibitor, which
can reproduce the oxidative and inflammatory status ob-
served in arthritic joints.
Fig. 2 Mitochondrial dysfunction increases CD68 (panel a) positive cells and IL-8 (panel b) in the synovial membrane. a Representative samples of
CD68 immunohistochemistry in synovial membrane. b Synovium sections were analyzed by immunohistochemistry for IL-8. Quantitative analysis of
CD68 (c) and IL-8 (d) positive cells. Values represent mean ± SEM (n = 5 independent synovial tissues). To assess non-immune non-specific binding
negative control was included in each experiment. * P ≤ 0.05 vs contralateral vehicle-injected knees. LPS, lipopolysaccharide; OLI, oligomycin
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The use of chemical mitochondrial inhibitors to in-
duce mitochondrial dysfunction in in vivo models is
widely accepted [46, 47]. However, the interpretation
of the effect of any pharmacological intervention is
always controversial because of the possibility that the
drug might present off-target activities. In this sense,
it is noteworthy that our model oligomycin treatment
resulted in an increase of mitochondrial ROS levels,
as well as an augmentation in the mitochondrial
mass. The enhanced generation of mitochondrial ROS
represent a key signal for mitochondrial dysfunction
[10]. Besides, the increase in mitochondrial mass is a
well-recognized compensatory mechanism in mito-
chondrial disease [48, 49].
Our macroscopic results show that oligomycin-
injected joints exhibit visible articular swelling and a
more significant increase of joint diameter than controls.
These macroscopic determinations denoted hyperplasia
and inflammatory processes in the joint that were con-
firmed later through histopathological and molecular
Fig. 3 Oligomycin increases ROS production in synovial tissue. Synovial tissue frozen sections from OLI-vehicle or OLI injected joints were incubated
with a cytoplasmic (DHE; a) or mitochondrial (MitoSox; b) superoxide-sensitive fluorescent dye (red). The nuclei were counterstained with DAPI (blue).
Representative images of the different color channels and their merge are shown. DHE (c) or MitoSox (d) fluorescence levels were measured
and calculated as described in Methods. Values, expressed in arbitrary units (AU), represent mean ± SEM (n = 7 independent synovial sections
for each condition). *P ≤ 0.05 vs OLI-vehicle knees. OLI, oligomycin; DAPI, 4′,6-diamidino-2-phenylindole; DHE, dihydroethidium; MitoSox, MitoSOX™
Red Mitochondrial Superoxide Indicator
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analysis. Multiple evidences suggest that inflammation
in synovial tissue plays an active role in the onset and
progression of articular disease, such as RA [17] or OA
[4, 6]. In our model, the synovial tissue in the oligomycin-
injected joints presented a marked increase in damage
score, showing an increase of cell layers at the lining, and
a continuous infiltration of inflammatory cells at the sub-
lining. In particular, a significant increase in the percent-
age of PMN and CD68+ cells was observed, in parallel
with a significant increase in IL-8 protein expression in
the synovium. Increased IL-8 expression is consistent with
our previous results in vitro in synovial cells and chondro-
cytes in which oligomycin caused a significant increase in
IL-8 mRNA and protein levels [23, 30].
A growing number of findings support the important
role of mitochondrial dysfunction-elicited ROS produc-
tion, and subsequently oxidative damage in chronic
arthropathies [1, 3]. By using an in vitro model, we pre-
viously described that oligomycin causes both cytosolic
and mitochondrial dose-dependent ROS generation in
synovial cells and chondrocytes [30, 41], which is re-
sponsible of an increased IL-8 expression [23, 30].
Therefore, we hypothesized that increased oxidative
stress resulting from defective mitochondria may drive
the inflammatory response induced by intra-articular
oligomycin exposure. When we evaluated the generation
of cytosolic and mitochondrial ROS in the synovial
tissue of oligomycin-injected joints, the results show that
cellular and mitochondrial ROS production increase
significantly more in the oligomycin-injected joints than
in control joints. In relation, the increase in mi-
tochondrial content is associated with defects in the
intracellular destruction of abnormal ROS-producing
mitochondria [49]. Interestingly, higher mitochondrial
mass, as measured by COX-IV signal, was observed in
the synovial tissue from oligomycin-injected joints than
in the control joints.
Consistent with this mitochondrial failure, more oxi-
dative damage, as measured by lipid peroxidation (4-
HNE), was also observed in synovial tissue from
oligomycin-injected joints. In synovial tissue from pa-
tients with inflammatory arthritis, 4-HNE is associated
with a greater frequency of mtDNA mutations, which
are associated with a higher presence of macroscopic
features of inflammation, increased expression of pro-
inflammatory cytokines, and a greater vascularization
Fig. 4 Oligomycin modulates COX-IV levels in the synovial tissue. a Immunofluorescence microscopy analysis of synovial tissue sections from OLI-
vehicle or OLI injected joints stained for COX-IV (red) with DAPI counterstaining (blue). Representative images are presented. b Fluorescence levels
were measured and calculated as described in Methods. Values, expressed in arbitrary units (AU), represent mean ± SEM (n = 7 independent
synovial sections). *P ≤ 0.05 vs OLI-vehicle knees. OLI, oligomycin; DAPI, 4′,6-diamidino-2-phenylindole; COX-IV, cytochrome c oxidase subunit IV
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and infiltration of CD68+ and CD3+ cells [11, 12, 50].
Altogether, these data could support the idea that the in-
flammatory response induced in the rat knee joint by ex-
posure to oligomycin is mediated by ROS production.
To further test the relevance of oligomycin-induced oxi-
dative and inflammatory damage, it would be interesting
to investigate the effects of antioxidants.
High levels of ROS, as well as the toxic products in-
duced by oxidative stress such as 4-HNE, are known to
activate the redox-sensitive transcription factor Nrf2.
For this reason, we measured by immunohistochemistry
the expression of Nrf2 in the synovial tissue from
oligomycin-injected joints. The results showed oligomy-
cin significantly up-regulated Nrf2 levels. In agreement
with this observation, we previously detected in vitro
that exposure of synovial cells to oligomycin causes Nrf2
activation (unpublished observations), and here, a higher
expression of this transcriptional factor was localized in
synovial tissue from end-stage OA patients. Besides,
Nrf2 activation was also observed in other articular
pathologies [31]. Interestingly, it has been recently de-
scribed that Nrf2 protects mitochondria against dysfunc-
tion and induces mitochondrial biogenesis [51]. Taken
together, these findings suggest Nrf2 up-regulation in
the joint could be a compensatory mechanism to coun-
teract mitochondrial defects and so, it would explain
higher mitochondrial mass observed in synovial tissue
from oligomycin-injected joints and in OA [13].
Over-activation of the catabolic program in the chon-
drocyte has been suggested as an important event and a
triggering mechanism that later drives the destructive
processes in articular pathologies [3]. For this reason, we
evaluated if mitochondrial dysfunction initially activated
an inflammatory response in this tissue. Specifically,
higher expression of CINC-1 (a murine homologue of
human IL-8) mRNA was detected in oligomycin-injected
joints. In agreement, ex vivo experiments showed in-
creased CINC-1 protein release by cartilage explants ob-
tained from equally treated joints. Similarly, we
previously demonstrated that oligomycin increased IL-8
Fig. 5 4-HNE and Nrf2 are modulated by oligomycin and Nrf2 is expressed in the synovial from OA patient. a Representative images of 4-HNE
immunohistochemistry synovial membrane sections from OLI-vehicle and OLI injected joints. b Representative images of Nrf2 immunohistochemistry
synovial membrane sections from OLI-vehicle and OLI injected joints. c Representative images of Nrf2 immunohistochemistry synovial membrane
sections obtained from healthy and OA patients. A score positive immunostaining for 4-HNE (d) and 2 (e) in control and oligomycin rats is shown, and
for healthy human donors and patients with OA in (f). Values represent mean ± SEM (n = 5 independent synovial tissues for rats; and n = 8
independent synovial tissues per each condition for human, respectively). To assess non-immune non-specific binding negative control was
included in each experiment. * P ≤ 0.05 vs contralateral vehicle-injected knees, and vs healthy human synovium. OLI, oligomycin; 4-HNE, anti-
4-hidroxi-2-nonenal; Nrf2, nuclear factor erythroid 2-related factor 2
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expression in cultured human chondrocytes [23]. CINC-
1 is a chemokine that attracts neutrophils to sites where
it is released. Interestingly, these inflammatory cells were
localized in the synovial tissue from oligomycin-injected
joints, suggesting the implication of chemokines released
by the cartilage and synovium in the cellular profile of
the synovial infiltrate.
Limitations
A limitation of the current study is the use of only oligo-
mycin for inducing mitochondrial dysfunction. Oligomy-
cin is a specific inhibitor of mitochondrial complex V;
however, a great number of findings suggest a role for
impairment of other mitochondrial respiratory com-
plexes in rheumatoid disorders [13, 17, 18, 23, 27, 30].
Thereby, in vivo studies exploring the impact of other
mitochondrial inhibitors, as well as protective effects of
antioxidants, should also be carried out in future. Be-
sides, in order to evaluate the early pathological re-
sponse in the joint, we performed an acute articular
model of mitochondrial dysfunction. Nevertheless,
evaluation of the impact of mitochondrial dysfunction at
long-term evolution is recommendable in following ana-
lysis. Another concern to still be elucidated will be to in-
vestigate whether mitochondrial impairment could
further aggravate the pathological pathways activated by
catabolic stress in the joint, such as we have previously
observed in vitro studies [23, 30].
Conclusions
In conclusion, the present study shows, for the first time
in an in vivo acute model, that oligomycin, an inhibitor
of mitochondrial function, causes an oxidative and in-
flammatory damage in synovial joints. Our results also
show that mitochondrial dysfunction in the joint in-
creases Nrf2 expression probably as a compensatory
mechanism to protect cells against oxidative and inflam-
matory stress generated. In summary, these data, along
with our previous findings highlight the importance of
mitochondrial impairment in the pathogenesis of ar-
thropathies. Developing treatments that target the main-
tenance of mitochondrial homeostasis should be
pursued in future studies.
Additional file
Additional file 1: Figure S1. Representative images of complete
histological sections stained with hematoxilyn and eosin. OLI-vehicle
(A, a) and OLI (B, b) injected joints. Original magnification: A, B (4X) and a, b
(20X). Higher synovial lining layer thickness (*), as well as neovascularization
(▲) and cellular infiltration (→) are observed in synovial tissue from
OLI-injected joints.). M, meniscus; TP, tibial plateau; FC, femoral condyle;
ST, synovial tissue. (TIFF 9220 kb)
Fig. 6 Effects of oligomycin on histopathological and inflammatory
changes in the cartilage. a Semi-quantitative score of pathological
alterations in cartilage was performed as described in Methods. Data
represent mean ± SEM (n = 5 independent samples). b CINC-1 mRNA
expression in cartilage. Values represent mean ± SEM (n = 5 samples
for each condition). c CINC-1 protein released by cartilage explants
from OLI-vehicle or OLI injected joints. Values are expressed as pg
CINC-1 protein released per μg of DNA (mean ± SEM, n = 6 samples
for each condition). *P ≤ 0.05 vs OLI-vehicle knees. OLI, oligomycin
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